Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Exp Hematol. 2011 Aug;39(8):829-36. doi: 10.1016/j.exphem.2011.05.001. Epub 2011 May 7.
Thrombopoietin stimulates megakaryopoiesis and platelet production by binding to its receptor, Mpl, on hematopoietic progenitor cells. Previously, a murine VB22B minibody for Mpl was shown to stimulate megakaryocyte colony formation in vitro and increase the platelet count in cynomolgus monkeys. In this study, we directly compared the effects of a humanized VB22B minibody (huVB22B) with those of thrombopoietin and eltrombopag under the hypothesis that Mpl agonists might have different biological effects on megakaryopoiesis, platelet production, intracellular signal transduction, and platelet function.
Human bone marrow-derived CD34(+) cells were used for colony formation assays and proplatelet formation assays in vitro. The DNA ploidy in megakaryocytes was analyzed by flow cytometry. Phosphorylation of signal transducers and activators of transcription and mitogen-activated protein kinase was detected by Western blotting using specific antibodies. The effects of the Mpl agonists on platelet aggregation were analyzed by aggregometry using human platelets.
HuVB22B was as potent as thrombopoietin and eltrombopag in its ability to form mature megakaryocytes using human CD34(+) cells in vitro. It did not affect granulocyte-macrophage or erythroid colony formation. HuVB22B increased the number of proplatelet-forming megakaryocytes more efficiently than thrombopoietin or eltrombopag. Despite stronger phosphorylation of signal transducers and activators of transcription and mitogen-activated protein kinase compared with thrombopoietin in human platelets, huVB22B did not enhance adenosine diphosphate- or collagen-induced platelet aggregation. Eltrombopag did not enhance agonist-induced platelet aggregation.
We found that huVB22B, eltrombopag, and thrombopoietin have different effects on megakaryopoiesis, platelet function, and intracellular signaling. The precise mechanisms for these different biological effects regarding stimulation through the same receptor, Mpl, remain to be elucidated.
血小板生成素通过与造血祖细胞上的受体 Mpl 结合,刺激巨核细胞生成和血小板生成。先前,一种用于 Mpl 的小鼠 VB22B 微型抗体已被证明可刺激体外巨核细胞集落形成,并增加食蟹猴的血小板计数。在这项研究中,我们根据假设,即 Mpl 激动剂可能对巨核细胞生成、血小板生成、细胞内信号转导和血小板功能有不同的生物学影响,直接比较了人源化 VB22B 微型抗体(huVB22B)与血小板生成素和艾曲泊帕的作用。
使用人骨髓来源的 CD34+细胞进行集落形成测定和体外产血小板测定。通过流式细胞术分析巨核细胞的 DNA 倍性。通过使用特异性抗体的 Western 印迹检测信号转导物和转录激活物以及丝裂原激活的蛋白激酶的磷酸化。通过使用人类血小板的聚集测定分析 Mpl 激动剂对血小板聚集的影响。
huVB22B 与血小板生成素和艾曲泊帕一样,能够在体外使用人 CD34+细胞形成成熟巨核细胞。它不影响粒细胞-巨噬细胞或红细胞集落形成。huVB22B 比血小板生成素或艾曲泊帕更有效地增加产血小板巨核细胞的数量。尽管与血小板生成素相比,huVB22B 在人血小板中信号转导物和转录激活物以及丝裂原激活的蛋白激酶的磷酸化更强,但它不能增强二磷酸腺苷或胶原诱导的血小板聚集。艾曲泊帕不能增强激动剂诱导的血小板聚集。
我们发现,huVB22B、艾曲泊帕和血小板生成素对巨核细胞生成、血小板功能和细胞内信号转导有不同的影响。关于通过相同的受体 Mpl 刺激产生这些不同生物学影响的确切机制仍有待阐明。